vs
ANI PHARMACEUTICALS INC（ANIP）とフォトロニクス（PLAB）の財務データ比較。上の社名をクリックして会社を切り替えられます
ANI PHARMACEUTICALS INCの直近四半期売上が大きい（$247.1M vs $210.4M、フォトロニクスの約1.2倍）。ANI PHARMACEUTICALS INCの純利益率が高く（11.1% vs 10.9%、差は0.2%）。ANI PHARMACEUTICALS INCの前年同期比売上増加率が高い（29.6% vs -5.5%）。ANI PHARMACEUTICALS INCの直近四半期フリーキャッシュフローが多い（$29.1M vs $25.2M）。過去8四半期でANI PHARMACEUTICALS INCの売上複合成長率が高い（34.1% vs -3.8%）
ANIファーマシューティカルズは米国に本社を置く特殊製薬会社で、後発医薬品とブランド処方薬の研究開発・製造・販売を行っています。主力製品分野は皮膚科、腫瘍、中枢神経系治療、感染症対策で、主に米国内の医療機関、調剤薬局、患者を対象としています。
フォトロニクスは米国の半導体フォトマスクメーカーで、2009年時点で世界第3位のフォトマスクサプライヤーです。電子ビームイニシアチブのメンバーでもあり、半導体製造に不可欠なフォトマスクを供給し、チップ製造の回路パターン転写工程を支えています。
ANIP vs PLAB — 直接比較
損益計算書 — Q4 FY2025 vs Q3 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $247.1M | $210.4M |
| 純利益 | $27.5M | $22.9M |
| 粗利率 | — | 33.7% |
| 営業利益率 | 14.1% | 22.9% |
| 純利益率 | 11.1% | 10.9% |
| 売上前年比 | 29.6% | -5.5% |
| 純利益前年比 | 367.5% | -32.4% |
| EPS（希薄化後） | $1.14 | $0.39 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $247.1M | — | ||
| Q3 25 | $227.8M | $210.4M | ||
| Q2 25 | $211.4M | $211.0M | ||
| Q1 25 | $197.1M | $212.1M | ||
| Q4 24 | $190.6M | $222.6M | ||
| Q3 24 | $148.3M | $211.0M | ||
| Q2 24 | $138.0M | $217.0M | ||
| Q1 24 | $137.4M | $216.3M |
| Q4 25 | $27.5M | — | ||
| Q3 25 | $26.6M | $22.9M | ||
| Q2 25 | $8.5M | $8.9M | ||
| Q1 25 | $15.7M | $42.9M | ||
| Q4 24 | $-10.3M | $33.9M | ||
| Q3 24 | $-24.2M | $34.4M | ||
| Q2 24 | $-2.3M | $36.3M | ||
| Q1 24 | $18.2M | $26.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | 33.7% | ||
| Q2 25 | — | 36.9% | ||
| Q1 25 | — | 35.6% | ||
| Q4 24 | — | 37.0% | ||
| Q3 24 | — | 35.6% | ||
| Q2 24 | — | 36.5% | ||
| Q1 24 | — | 36.6% |
| Q4 25 | 14.1% | — | ||
| Q3 25 | 15.9% | 22.9% | ||
| Q2 25 | 6.6% | 26.4% | ||
| Q1 25 | 13.3% | 24.6% | ||
| Q4 24 | -2.3% | 25.1% | ||
| Q3 24 | -13.8% | 24.7% | ||
| Q2 24 | 3.7% | 25.8% | ||
| Q1 24 | 14.8% | 26.6% |
| Q4 25 | 11.1% | — | ||
| Q3 25 | 11.7% | 10.9% | ||
| Q2 25 | 4.0% | 4.2% | ||
| Q1 25 | 8.0% | 20.2% | ||
| Q4 24 | -5.4% | 15.2% | ||
| Q3 24 | -16.3% | 16.3% | ||
| Q2 24 | -1.7% | 16.7% | ||
| Q1 24 | 13.2% | 12.1% |
| Q4 25 | $1.14 | — | ||
| Q3 25 | $1.13 | $0.39 | ||
| Q2 25 | $0.36 | $0.15 | ||
| Q1 25 | $0.69 | $0.68 | ||
| Q4 24 | $-0.45 | $0.54 | ||
| Q3 24 | $-1.27 | $0.55 | ||
| Q2 24 | $-0.14 | $0.58 | ||
| Q1 24 | $0.82 | $0.42 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $285.6M | $575.8M |
| 総負債低いほど良い | — | $16.0K |
| 株主資本純資産 | $540.7M | $1.1B |
| 総資産 | $1.4B | $1.8B |
| 負債/資本比率低いほどレバレッジが低い | — | 0.00× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $285.6M | — | ||
| Q3 25 | $262.6M | $575.8M | ||
| Q2 25 | $217.8M | $558.4M | ||
| Q1 25 | $149.8M | $642.2M | ||
| Q4 24 | $144.9M | $640.7M | ||
| Q3 24 | $145.0M | $606.4M | ||
| Q2 24 | $240.1M | $559.9M | ||
| Q1 24 | $228.6M | $521.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | $16.0K | ||
| Q2 25 | — | $19.0K | ||
| Q1 25 | — | $21.0K | ||
| Q4 24 | — | $25.0K | ||
| Q3 24 | — | $28.0K | ||
| Q2 24 | — | $2.5M | ||
| Q1 24 | — | $2.7M |
| Q4 25 | $540.7M | — | ||
| Q3 25 | $505.8M | $1.1B | ||
| Q2 25 | $436.8M | $1.1B | ||
| Q1 25 | $418.6M | $1.1B | ||
| Q4 24 | $403.7M | $1.1B | ||
| Q3 24 | $405.9M | $1.1B | ||
| Q2 24 | $455.8M | $1.0B | ||
| Q1 24 | $452.0M | $1.0B |
| Q4 25 | $1.4B | — | ||
| Q3 25 | $1.4B | $1.8B | ||
| Q2 25 | $1.3B | $1.7B | ||
| Q1 25 | $1.3B | $1.7B | ||
| Q4 24 | $1.3B | $1.7B | ||
| Q3 24 | $1.3B | $1.6B | ||
| Q2 24 | $920.8M | $1.6B | ||
| Q1 24 | $914.5M | $1.6B |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.00× | ||
| Q2 25 | — | 0.00× | ||
| Q1 25 | — | 0.00× | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | 0.00× | ||
| Q2 24 | — | 0.00× | ||
| Q1 24 | — | 0.00× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $30.4M | $50.1M |
| フリーキャッシュフロー営業CF - 設備投資 | $29.1M | $25.2M |
| FCFマージンFCF / 売上 | 11.8% | 12.0% |
| 設備投資強度設備投資 / 売上 | 0.5% | 11.8% |
| キャッシュ転換率営業CF / 純利益 | 1.10× | 2.19× |
| 直近12ヶ月FCF直近4四半期 | $171.4M | $64.5M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $30.4M | — | ||
| Q3 25 | $44.1M | $50.1M | ||
| Q2 25 | $75.8M | $31.5M | ||
| Q1 25 | $35.0M | $78.5M | ||
| Q4 24 | $15.9M | $68.4M | ||
| Q3 24 | $12.5M | $75.1M | ||
| Q2 24 | $17.4M | $76.5M | ||
| Q1 24 | $18.3M | $41.5M |
| Q4 25 | $29.1M | — | ||
| Q3 25 | $38.0M | $25.2M | ||
| Q2 25 | $71.8M | $-29.1M | ||
| Q1 25 | $32.5M | $43.3M | ||
| Q4 24 | $13.5M | $25.2M | ||
| Q3 24 | $7.7M | $50.7M | ||
| Q2 24 | $13.0M | $56.5M | ||
| Q1 24 | $13.7M | $-1.8M |
| Q4 25 | 11.8% | — | ||
| Q3 25 | 16.7% | 12.0% | ||
| Q2 25 | 34.0% | -13.8% | ||
| Q1 25 | 16.5% | 20.4% | ||
| Q4 24 | 7.1% | 11.3% | ||
| Q3 24 | 5.2% | 24.0% | ||
| Q2 24 | 9.4% | 26.0% | ||
| Q1 24 | 10.0% | -0.8% |
| Q4 25 | 0.5% | — | ||
| Q3 25 | 2.7% | 11.8% | ||
| Q2 25 | 1.9% | 28.7% | ||
| Q1 25 | 1.3% | 16.6% | ||
| Q4 24 | 1.3% | 19.4% | ||
| Q3 24 | 3.2% | 11.6% | ||
| Q2 24 | 3.2% | 9.2% | ||
| Q1 24 | 3.3% | 20.0% |
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | 2.19× | ||
| Q2 25 | 8.87× | 3.55× | ||
| Q1 25 | 2.23× | 1.83× | ||
| Q4 24 | — | 2.02× | ||
| Q3 24 | — | 2.18× | ||
| Q2 24 | — | 2.11× | ||
| Q1 24 | 1.00× | 1.59× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
PLAB
| High End Integrated Circuits | $53.6M | 25% |
| High End Flat Panel Displays | $53.5M | 25% |
| KR | $43.7M | 21% |
| Other | $42.1M | 20% |
| Mainstream Flat Panel Displays | $9.1M | 4% |
| Transferred At Point In Time | $8.4M | 4% |
